Cellular immunological functions in patients with myelodysplasia
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.
Blood Cancer J 2014;4():e189. Epub 2014 mar 7
Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.
Oncoimmunology 2013 Feb 1;2(2):e23138.
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.
Expert Opin Investig Drugs 2010 Feb;19(2):169-83.
The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications.
Curr Top Microbiol Immunol 2010;341():149-72.
The chemokine system in experimental and clinical hematology.
Curr Top Microbiol Immunol 2010;341():3-12.
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Eur J Haematol 2010 Mar;84(3):239-51. Epub 2009 nov 17
1. Novel pre-clinical models of myelodysplastic syndrome (MDS).
Experimental Hematology, supplement 8, volume 42, 2014
The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?
Expert Rev Hematol.
Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.
J Biomed Biotechnol.
Circulating T cells derived from patients with low risk myelodysplastic
Poster ASH, publication nr. 4018 December 2010